Clinical trial
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the…
NCT00195299 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195299 |
|---|---|
| Title | Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck |
| Official title | An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Squamous Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Temsirolimus |
| Enrollment | 20 |
| Start date | Apr 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 27, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: